Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company

Cancer Immunotherapy Sector Predicted to Surge to USD 9 Billion Across Major Pharma Through 2022

By BiotechDaily International staff writers
Posted on 30 Jul 2014
The immunotherapy market will experience substantial growth through 2022, increasing from USD 1.1 billion in 2012 to nearly USD 9 billion in 2022 (corresponding to 23.8% annual growth) in the United Kingdom, United States, France, Germany, Italy, Spain, and Japan, according to recent market research.

This notable growth will be fueled by the anticipated market entry of nine novel immunotherapies--including four novel immune checkpoint inhibitors and five novel therapeutic vaccines—in new oncology indications and/or patient populations, according to Decision Resources Group (Burlington, MA, USA). Combined, Bristol-Myers Squibb’s anti-CTLA-4 agent Yervoy and innovative immune checkpoint inhibitors that target the anti-programmed cell death-1/programmed death-ligand-1 (PD-1/PD-L1) pathway—including Bristol-Myers Squibb/Ono Pharmaceutical’s nivolumab, Merck & Co.'s pembrolizumab (MK-3475), Roche/Genentech/Chugai’s MPDL-3280A and AstraZeneca/MedImmune’s MEDI4736—should dominate the immunotherapy market and capture a remarkable 85% market share in 2022.

Other key findings from the Pharmacor Immunotherapies advisory service include: potential of anti-PD-1/PD-L1 agents: Interviewed experts are considerably excited about the potential of anti-PD-1/PD-L1 agents based on encouraging data released to date in multiple oncology indications. The added prospect of using PD-L1 expression as a potential predictive biomarker for customizing treatment fascinated interviewed experts; however, they remain watchful on this point, noting that considerable heterogeneity exists in PD-L1 expression and that good objective responses have also been reported in patients considered to have no or low levels of PD-L1 expression.

Because of the impressive early-phase data presented at the 2014 annual meeting of the American Society for Clinical Oncology (ASCO), held May 30-June 3, 2014, in Chicago (IL, USA), interviewed experts expressed enthusiasm for combination approaches involving immunotherapies—including dual blockade of the immune checkpoint pathway, combinations of immune checkpoint inhibitors with therapeutic cancer vaccines and combinations of immune checkpoint inhibitors with chemotherapy.

The therapeutic vaccines segment will see, according to Decision Resources Group, 13.6% annual sales growth over the 2012 to 2022 forecast period, although, with combined major-market sales reaching USD 1.2 billion in 2022, these agents will not reach the commercial success of immune checkpoint inhibitors.

Decision Resources Group senior business insights analyst Khurram Nawaz, MSc, commented, “A plethora of immunotherapies are in development across a wide range of oncology indications, making this drug class one of the most exciting to watch. We anticipate that nivolumab will be the sales-leading agent among immunotherapies. However, it will face direct and intense competition from other anti-PD-1/PD-L1 agents—notably from pembrolizumab in malignant melanoma and non-small-cell lung cancer—and to a lesser degree, from MPDL-3280A in non-small-cell lung cancer. Interviewed experts express mixed reactions to therapeutic vaccines and note the challenges in monitoring the efficacy of these agents. Nevertheless, they are hopeful that some vaccines will provide new therapeutic options and hold greatest promise as part of combination strategies.”

Decision Resources Group offers information and insights on critical issues within the healthcare industry.

Related Links:

Decision Resources Group



view channel
Image: representation of a protein (blue), which contains three zinc fingers in complex with DNA (orange). The coordinating amino acid residues and zinc ions (green) are highlighted (Photo courtesy of Wikimedia Commons).

Molecular Sensors Generated by Synthetic Biology Technique Using Intein-Based Protein Splicing

Biotech researchers have used intein-based protein splicing to generate synthetic protein components that are able to detect specific DNA sequences and subsequently trigger a desired intracellular response... Read more

Drug Discovery

view channel
Image: Endoscopic image of a bowel section known as the sigmoid colon afflicted with ulcerative colitis. The internal surface of the colon is blotchy and broken in places (Photo courtesy of Wikimedia Commons).

Orally Delivered Curcumin-Loaded Microparticles Effectively Treat Mouse Model of Ulcerative Colitis

Microparticles (MPs) loaded with the efficient anti-inflammatory agent curcumin were found to effectively treat a mouse model of ulcerative colitis. Ulcerative colitis is a chronic relapsing disease... Read more

Lab Technologies

view channel

New Genomic Research Kit Simplifies Exome Studies

An exciting new tool is now available for biotech researchers working in the field of genomic analysis. The human exome is critical to our genetic make-up and is generally accepted as having the greatest influence on how the genetic blueprint is utilized. The exome is defined as all coding exons in the genome and is... Read more


17 Oct 2015 - 21 Oct 2015
25 Oct 2015 - 29 Oct 2015
16 Nov 2015 - 19 Nov 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.